12. Semenza GL (2010) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20: 51–56. 13. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, et al. (2003) The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22: 3213–3220. 14. Brahimi-Horn MC, Chiche J, Pouyssegur J (2007) Hypoxia and cancer. J Mol Med 85: 1301–1307. 15. Fraisl P, Mazzone M, Schmidt T, Carmeliet P (2009) Regulation of angiogenesis by oxygen and metabolism. Dev Cell 16: 167–179. 16. Green H, Goldberg B (1964) Collagen and cell protein synthesis by an established mammalian fibroblast cell line. Nature 204: 347–349. 17. Hunt TK, Aslam RS, Beckert S, Wagner S, Ghani QP, et al. (2007) Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms. Antioxid Redox Signal 9: 1115–1124. 18. Trabold O, Wagner S, Wicke C, Scheuenstuhl H, Hussain MZ, et al. (2003) Lactate and oxygen constitute a fundamental regulatory mechanism in wound healing. Wound Repair Regen 11: 504–509. 19. Constant JS, Feng JJ, Zabel DD, Yuan H, Suh DY, et al. (2000) Lactate elicits vascular endothelial growth factor from macrophages: a possible alternative to hypoxia. Wound Repair Regen 8: 353–360. 20. Xiong M, Elson G, Legarda D, Leibovich SJ (1998) Production of vascular endothelial growth factor by murine macrophages: regulation by hypoxia, lactate, and the inducible nitric oxide synthase pathway. Am J Pathol 153: 587–598. 21. Lu H, Forbes RA, Verma A (2002) Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277: 23111–23115. 22. Lu H, Dalgard CL, Mohyeldin A, McFate T, Tait AS, et al. (2005) Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem 280: 41928–41939. 23. Vegran F, Boidot R, Michiels C, Sonveaux P, Feron O (2011) Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Res 71: 2550–2560. 24. Walenta S, Schroeder T, Mueller-Klieser W (2004) Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr Med Chem 11: 2195–2204. 25. Walenta S, Snyder S, Haroon ZA, Braun RD, Amin K, et al. (2001) Tissue gradients of energy metabolites mirror oxygen tension gradients in a rat mammary carcinoma model. Int J Radiat Oncol Biol Phys 51: 840–848. 26. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, et al. (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118: 3930–3942. 27. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358: 2039–2049. 28. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, et al. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604–4613. 29. Calvani M, Rapisarda A, Uranchimeg B, Shoemaker RH, Melillo G (2006) Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 107: 2705–2712. 30. Li F, Sonveaux P, Rabbani ZN, Liu S, Yan B, et al. (2007) Regulation of HIF- 1alpha stability through S-nitrosylation. Mol Cell 26: 63–74. 31. Wilkinson JH, Walter SJ (1972) Oxamate as a differential inhibitor of lactate dehydrogenase isoenzymes. Enzyme 13: 170–176. 32. Halestrap AP, Price NT (1999) The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 343 Pt 2: 281–299. 33. Halestrap AP, Meredith D (2004) The SLC16 gene family-from monocarbox- ylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch 447: 619–628. 34. Manning Fox JE, Meredith D, Halestrap AP (2000) Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle. J Physiol 529 Pt 2: 285–293. 35. Masson V, Devy L, Grignet-Debrus C, Bernt S, Bajou K, et al. (2002) Mouse aortic ring assay: A new approach of the molecular genetics of angiogenesis. Biol Proced Online 4: 24–31. 36. Sonveaux P, Martinive P, DeWever J, Batova Z, Daneau G, et al. (2004) Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis. Circ Res 95: 154–161. 37. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, et al. (2004) Loss of HIF- 1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6: 485–495. 38. Deudero JJ, Caramelo C, Castellanos MC, Neria F, Fernandez-Sanchez R, et al. (2008) Induction of hypoxia-inducible factor 1alpha gene expression by vascular endothelial growth factor. J Biol Chem 283: 11435–11444. 39. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029–1033. 40. Feron O (2009) Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 92: 329–333. 41. DeBerardinis RJ, Cheng T (2010) Q’s next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29: 313–324. Targeting MCT1 Blocks Tumor Angiogenesis 42. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E (2006) Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res 66: 632–637. 43. Julien C, Payen JF, Tropres I, Farion R, Grillon E, et al. (2004) Assessment of vascular reactivity in rat brain glioma by measuring regional blood volume during graded hypoxic hypoxia. Br J Cancer 91: 374–380. 44. Rauch C, Pluen A, Foster N, Loughna P, Mobasheri A, et al. (2010) On some aspects of the thermodynamic of membrane recycling mediated by fluid phase endocytosis: evaluation of published data and perspectives. Cell Biochem Biophys 56: 73–90. 45. Paulusma CC, Oude Elferink RP (2005) The type 4 subfamily of P-type ATPases, putative aminophospholipid translocases with a role in human disease. Biochim Biophys Acta 1741: 11–24. 46. Wilbers KH, Haest CW, von Benthem M, Deuticke B (1979) Influence of enzymatic phospholipid cleavage on the permeability of the erythrocyte membrane. II. Protein-mediated transfer of monosaccharides and anions. Biochim Biophys Acta 554: 400–409. 47. Mahon PC, Hirota K, Semenza GL (2001) FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15: 2675–2686. 48. Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, et al. (2006) Concordant regulation of gene expression by hypoxia and 2-oxoglutarate- dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem 281: 15215–15226. 49. Semenza GL (2009) Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood 114: 2015–2019. 50. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, et al. (1998) Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394: 485–490. 51. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, et al. (1998) Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12: 149–162. 52. Ryan HE, Lo J, Johnson RS (1998) HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17: 3005–3015. 53. Le Bras A, Lionneton F, Mattot V, Lelievre E, Caetano B, et al. (2007) HIF- 2alpha specifically activates the VE-cadherin promoter independently of hypoxia and in synergy with Ets-1 through two essential ETS-binding sites. Oncogene 26: 7480–7489. 54. Bertram JS, Janik P (1980) Establishment of a cloned line of Lewis Lung Carcinoma cells adapted to cell culture. Cancer Lett 11: 63–73. 55. Taper HS, Woolley GW, Teller MN, Lardis MP (1966) A new transplantable mouse liver tumor of spontaneous origin. Cancer Res 26: 143–148. 56. Martinive P, De Wever J, Bouzin C, Baudelet C, Sonveaux P, et al. (2006) Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery. Mol Cancer Ther 5: 1620–1627. 57. Diepart C, Verrax J, Calderon PB, Feron O, Jordan BF, et al. (2010) Comparison of methods for measuring oxygen consumption in tumor cells in vitro. Anal Biochem 396: 250–256. 58. Sonveaux P, Brouet A, Havaux X, Gregoire V, Dessy C, et al. (2003) Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res 63: 1012–1019. 59. Feron O, Belhassen L, Kobzik L, Smith TW, Kelly RA, et al. (1996) Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 271: 22810–22814. 60. Quintero M, Colombo SL, Godfrey A, Moncada S (2006) Mitochondria as signaling organelles in the vascular endothelium. Proc Natl Acad Sci U S A 103: 5379–5384. 61. Bouzin C, Brouet A, De Vriese J, DeWever J, Feron O (2007) Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identi- fication of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol 178: 1505–1511. 62. Dimmeler S, Dernbach E, Zeiher AM (2000) Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett 477: 258–262. 63. Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, et al. (2001) Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 89: 866–873. 64. Del Prete E, Lutz TA, Scharrer E (2004) Inhibition of glucose oxidation by alpha-cyano-4-hydroxycinnamic acid stimulates feeding in rats. Physiol Behav 80: 489–498. 65. Dewhirst MW, Kimura H, Rehmus SW, Braun RD, Papahadjopoulos D, et al. (1996) Microvascular studies on the origins of perfusion-limited hypoxia. Br J Cancer Suppl 27: S247–S251. 66. Sonveaux P, Dessy C, Brouet A, Jordan BF, Gregoire V, et al. (2002) Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery. FASEB J 16: 1979–1981. PLoS ONE | www.plosone.org 13 March 2012 | Volume 7 | Issue 3 | e33418